Faculty of Medicine, University of Malaya Centre for Proteomics Research, University of Malaya, Kuala Lumpur, Malaysia.
Electrophoresis. 2012 Jul;33(12):1855-62. doi: 10.1002/elps.201100608.
Diagnosis of prostate cancer (PCa) is currently much reliant on the invasive and time-consuming transrectal ultrasound-guided biopsy of the prostate gland, particularly in light of the inefficient use of prostate-specific antigen as its biomarker. In the present study, we have profiled the sera of patients with PCa and benign prostatic hyperplasia (BPH) using the gel- and lectin-based proteomics methods and demonstrated the significant differential expression of apolipoprotein AII, complement C3 beta chain fragment, inter-alpha-trypsin inhibitor heavy chain 4 fragment, transthyretin, alpha-1-antitrypsin, and high molecular weight kininogen (light chain) between the two groups of patients' samples. Our data are suggestive of the potential use of the serum proteins as complementary biomarkers to effectively discriminate PCa from BPH, although this requires further extensive validation on clinically representative populations.
前列腺癌 (PCa) 的诊断目前非常依赖于经直肠超声引导的前列腺活检，这是一种有创且耗时的方法，尤其是考虑到前列腺特异性抗原作为生物标志物的效率不高。在本研究中，我们使用基于凝胶和凝集素的蛋白质组学方法对 PCa 和良性前列腺增生 (BPH) 患者的血清进行了分析，并证明了载脂蛋白 AII、补体 C3β 链片段、α1-抗胰蛋白酶、转甲状腺素蛋白和高分子量激肽原（轻链）在两组患者样本之间存在显著的差异表达。我们的数据表明，这些血清蛋白有可能作为补充生物标志物，有效地将 PCa 与 BPH 区分开来，但这需要在具有代表性的临床人群中进行进一步的广泛验证。
